The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20090277: Morgan Stanley; Morgan Stanley Smith Barney LLC
Teva Pharmaceutical Industries Ltd., a corporation, and Barr Pharmaceuticals, Inc., a corporation, In the Matter of
In December 2008, the Commission settled antitrust concerns raised by the proposed $8.9 billion acquisition of Barr Pharmaceuticals by Teva Pharmaceutical Industries. The proposed acquisition would have lessened competition in the markets for 17 commonly used generic medications including drugs used in the treatment of cancer, bacterial infections, diabetes, acid reflux, and depression as well as several varieties of oral contraceptives. According to the Commission’s complaint, the acquisition would have likely led to higher prices for consumers through the removal of one of only four competitors in each of these markets. The Commission’s consent agreement requires both Teva and Barr to sell assets in 29 U.S. markets to either Watson Pharmaceuticals or Qualitest Pharmaceuticals.
Alternatel, Inc., G.F.G. Enterprises LLC, also d/b/a Mystic Prepaid, Voice Prepaid, Inc., Telecom Express, Inc., Telexpress, Inc., Voice Distributors, Inc., et al.
0902005 Informal Interpretation
Genica Corporation and Compgeeks.com; Analysis of Proposed Consent Order to Aid Public Comment
20090281: Autonomy Corporation PLC; Interwoven, Inc.
Complete Weightloss Center, Inc., et al.
20090264: Electricite de France S.A.; Constellation Energy Group, Inc.
Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules
Getinge AB and Databascope Corp.; Analysis of Agreement containing Consent Order to Aid Public Comment
20090243: Glen A. Taylor; Golden Oval Eggs, LLC
0902001 Informal Interpretation
Franciscan Missionaries of Our Lady Health System, Inc./Cappella Healthcare Inc.
King Pharmaceuticals, Inc., and Alpharma Inc., In the Matter of
In late 2008, the Commission issued a consent order to restore competition in the market for oral long-acting opioids (LAOs). The FTC intervened in King Pharmaceutical’s proposed $1.6 billion acquisition of rival drug-maker Alpharma Inc. because the transaction would have joined the two leading producers of morphine sulfate oral LAO’s in the United States, a market which was already highly concentrated and which had annual sales of $4 billion in 2007. In order to maintain competition in the market, the Commission’s consent order requires King to divest its Kadian business to Actavis, a company which already manufactured the drug for King, and which could then produce a generic equivalent of the drug sooner than would have been permitted under King’s patent, which would not have expired until 2010.